(Solid Tumors) Medical Journal: Anti-Tissue Factor Antibody-Drug Conjugate Tisotumab Vedotin
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Anti-Tissue Factor Antibody-Drug Conjugate Tisotumab Vedotin
- March 1, 2019
- Reading time: 1 minute
The response rate for patients with advanced solid tumors treated with the anti-tissue factor (TF) antibody-drug conjugate Tisotumab vedotin was 15.6%.
On February 7, 2019, Dr. Johann S. de Bono published Phase 1-2 clinical trial results in the medical journal The Lancet, evaluating Tisotumab vedotin — an anti-tissue factor (TF) antibody-drug conjugate — in patients with advanced or metastatic solid tumors. The study enrolled patients with six cancer types: ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, prostate cancer, esophageal cancer, head and neck cancer, and non-small cell lung cancer. Mild side effects were observed, including epistaxis (nosebleed), nausea, and fatigue. Dr. de Bono noted that patients tolerated the drug well and that the therapeutic effect was promising.
Source: Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial (Lancet Oncology, February 07, 2019)
Tags: #OvarianCancer #CervicalCancer #EndometrialCancer #BladderCancer #EsophagealCancer #HeadAndNeckCancer #ProstateCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4